Alexion Pharmaceuticals Inc.
Boston, MA Doing business as Alexion Pharmaceuticals Inc.
- UEI
- DKCXLGANZAN3
- CAGE
- 4EXK1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Alexion Pharmaceuticals Inc.
DKCXLGANZAN3
- Alexion Pharma International SARL FKJ6ZGM5A7P7
- Portola Pharmaceuticals, Inc. FH2MKRASLYM3
-
Alexion Pharmaceuticals Inc.
DKCXLGANZAN3
- SAM.gov registration date
- Physical address
- 121 Seaport Blvd, Boston, MA 02210, USA
- Website
- alexion.com
- Founded
- 1992
- Employees
- 1K-5K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Strensiq 80 MG | Veterans Integrated Service Network 5 | $104,650 | |
| Strensiq 80 MG/0.8 ML INJ. | Veterans Integrated Service Network 20 | $1,255,805 | |
| Strensiq | Veterans Integrated Service Network 20 | $626,866 | |
| Order for pharmaceutical strensiq 80MG | Veterans Integrated Service Network 20 | $522,487 | |
| Strensiq | Veterans Integrated Service Network 20 | $187,948 |
About Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc., headquartered in Boston, Massachusetts, is a foreign-owned, for-profit biopharmaceutical company specializing in rare disease therapeutics. The company is registered in SAM.gov as a corporate entity and maintains an active federal vendor status, with its registration expiring on December 15, 2026. Through its federal contracting relationships, Alexion provides specialized pharmaceutical products to support the treatment of rare genetic disorders affecting eligible patients within the U.S. federal healthcare system, demonstrating sustained capability in delivering critical therapeutic medications to government agencies.
Alexion's federal contract work has been exclusively focused on the supply of Strensiq, a specialized injectable medication used to treat perinatal/infantile- and juvenile-onset hypophosphatasia, a rare genetic disorder affecting both pediatric and juvenile populations. The company has received five delivery orders from the Department of Veterans Affairs, specifically through Veterans Integrated Service Networks 20 and 8, with contract values ranging from approximately $70,658 to $1.25 million. These delivery orders were awarded between August 2022 and December 2025, with performance locations in Boston, Massachusetts and Carrollton, Texas. All contract awards have been issued under the Pharmaceuticals and Drugs General Services Administration Schedule (FSS-61-IB) with firm fixed-price structures and no set-aside designations, indicating open competition procurement processes. The delivery orders reflect incremental procurement needs across VA medical centers and clinics, with ultimate completion dates extending from August 2022 through December 2026, ensuring continuous availability of this specialized therapeutic across the VA healthcare system.
Alexion holds a single-award Blanket Purchase Agreement (BPA) with the Department of Veterans Affairs National Acquisition Center, valued at $4.24 million and active through August 31, 2026. Established on September 1, 2022, this BPA operates under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) and streamlines the procurement and delivery of Strensiq to VA medical centers and clinics nationwide without set-aside restrictions. The BPA mechanism allows Veterans Integrated Service Networks and individual VA facilities to place individual delivery orders as needed, facilitating continuity of care for veterans requiring this rare disease treatment. All work is performed directly by Alexion from its Boston facility, and the agreement includes provisions for pricing updates through 2026 to ensure continued market-based pricing. The recent delivery orders documented in Alexion's award history demonstrate the active utilization of this BPA structure, with individual task orders issued throughout 2023, 2024, and 2025 to support ongoing pharmaceutical needs across the VA system.
Contract vehicles
Quick answers
What is Alexion Pharmaceuticals Inc.'s UEI?
Alexion Pharmaceuticals Inc.'s Unique Entity ID (UEI) in SAM.gov is DKCXLGANZAN3.
What is Alexion Pharmaceuticals Inc.'s CAGE code?
Alexion Pharmaceuticals Inc.'s CAGE code is 4EXK1.
What is Alexion Pharmaceuticals Inc.'s primary NAICS code?
Alexion Pharmaceuticals Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Alexion Pharmaceuticals Inc. located?
Alexion Pharmaceuticals Inc.'s physical address in SAM.gov is 121 Seaport Blvd, Boston, MA 02210, USA.
Is Alexion Pharmaceuticals Inc. registered in SAM.gov?
Yes. Alexion Pharmaceuticals Inc.'s SAM.gov registration is active through April 27, 2027.
Which contract vehicles does Alexion Pharmaceuticals Inc. hold?
Alexion Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Alexion Pharmaceuticals Inc.'s most recent federal award?
Alexion Pharmaceuticals Inc.'s most recent federal contract award is Strensiq 80 MG (36C24526N0739), from Veterans Integrated Service Network 5, on July 21, 2026.
On GovTribe
See Alexion Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors